Becton Dickinson Pays $22M To Settle Syringe Antitrust Suits
Becton Dickinson & Co. has struck a $22 million settlement agreement with hospitals and pharmacies whose class actions accused the New Jersey-based medical technology company of stifling competition from other hypodermic...To view the full article, register now.
Already a subscriber? Click here to view full article